Biosimilar Use, Cost Trends In Medicare Part B Will Be Examined By HHS Inspector General

 
• By Cathy Kelly
  
magnified money
OIG Will Investigate Extent Of Savings From Biosimilars • Source: Alamy

More from Biosimilars

More from Products